Coherus BioSciences aims to continue balancing internally-developed biosimilars with in-licensed product opportunities, as the US-based player enters its 2020 financial year cash flow positive from operations following a virtual full year of wholly-owned Udenyca (pegfilgrastim-cbqv) sales.
Denny Lanfear, Coherus’ president, CEO and chairman, told investors at the company’s year-end financial results call, “I think that it's...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?